SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mad2 who wrote (1820)12/6/1999 3:20:00 PM
From: Eric Fader  Read Replies (1) of 5582
 
I beg to differ. A proclamation like that, based on technical analysis applied to a thinly traded stock, would not be reliable even if its source were not someone with an acknowledged bias.

Whether GUMM closes below any particular "magic number" as a result of short-term selling or manipulation will neither influence nor foreshadow the stock's performance once the backlog of Zicam orders is cleared. My understanding is that, at such time, the advertising campaign would finally begin in full force (Mike, Dan, Bo or Howard - is that still believed to be correct?) and Zicam's journey toward "household name" status will accelerate, along with GUMM's stock price. Furthermore, the announcement of the results of the second clinical study will be a lightning bolt that will smite short-sellers without warning.

That's all from me for today. This back-and-forth stuff is getting tedious. I still calmly and confidently expect a $30 stock price and a likely retail investor buying frenzy within a couple of months.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News